• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文会议>International Conference on Management Science and Management Innovation >Analysis of the World Top 1000 Corporations RD Investment in 2014: With Focus on those Chinese Corporations
【24h】

Analysis of the World Top 1000 Corporations RD Investment in 2014: With Focus on those Chinese Corporations

机译：2014年世界前1000家公司研发投资的分析：专注于那些中国公司

获取原文
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Each year, the European Union's (EU) Economics of Industrial Research & Innovation (IRI) project group will publish a report entitled "R&D Scoreboard" which summarizes the world top 1,500 to 2,500 corporations (number varies from year to year) R&D investment in the previous year. In this paper, the author will extract the top 1000 corporations from this EU 2015 report, then analyze and compare the Chinese corporations' performance versus the rest of the pool. By comparing the investment in different sectors, we found that the Chinese corporations' primary R&D investment, similar to other regions, were in the construction, IT industry, transportation, and energy sectors. However, different from other regions, Chinese R&D investment in the pharmaceuticals and biotechnology is significantly less than the rest of the world. Our next step is to compare the annual profit margin with the R&D investment percentages of these Chinese corporations. The objective is to verify whether the Chinese corporations will stick to the sustainable strategy of continuously increasing in R&D investment, regardless of the short-term revenue fluctuations.
机译：每年，欧盟（欧盟）工业研究和创新经济学（IRI）项目集团将发布题为“研发记分牌”的报告，该报告总结了世界前1,500至2,500家公司（数量从一年中的数量不同）研发投资上一年。在本文中，提交人将从本欧盟2015年报告中提取前1000家公司，然后分析和比较中国公司的业绩与池的其余部分。通过比较不同部门的投资，我们发现中国企业的初级研发投资，类似于其他地区，在建设，IT行业，运输和能源领域。然而，与其他地区不同，中国研发投资的药物和生物技术的投资明显不到世界其他地区。我们的下一步是将年度利润率与这些中国公司的研发投资百分比进行比较。目的是验证中国公司是否将坚持不断增加研发投资的可持续战略，无论短期收入波动如何。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号